Pirfenidone has been licensed by the European Medicines Agency (EMA) for the treatment of mild to moderate idiopathic pulmonary fibrosis.
|15/12/2011||05/01/2012||Full Pharmacoeconomic Evaluation Recommended|
|26/11/2012||20/03/2013||Reimbursement Not Recommended|
The NCPE believe that, at the submitted price, pirfenidone is not cost-effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis.
The HSE has approved reimbursement following confidential price negotiations.